Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
0(0%)
Results Posted
22%(2 trials)

Phase Distribution

Ph phase_2
5
56%
Ph phase_1
3
33%
Ph phase_3
1
11%

Phase Distribution

3

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
3(33.3%)
Phase 2Efficacy & side effects
5(55.6%)
Phase 3Large-scale testing
1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(9)

Detailed Status

Completed9

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (33.3%)
Phase 25 (55.6%)
Phase 31 (11.1%)

Trials by Status

completed9100%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_2

A Randomized Prospective Clinical Trial of Fel d 1 Peptide Immunotherapy

NCT02311413
completedphase_3

Phase III Cat-PAD Study

NCT01620762
completedphase_2

Paediatric Safety Study in Cat-PAD

NCT01921257
completedphase_1

Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis

NCT01383603
completedphase_1

Identification of Potential Biomarkers of Peptide Immunotherapy. Part 1 - Proteomics Analysis

NCT01383590
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT02311413Phase 2

A Randomized Prospective Clinical Trial of Fel d 1 Peptide Immunotherapy

Completed
NCT01620762Phase 3

Phase III Cat-PAD Study

Completed
NCT01921257Phase 2

Paediatric Safety Study in Cat-PAD

Completed
NCT01383603Phase 1

Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis

Completed
NCT01383590Phase 1

Identification of Potential Biomarkers of Peptide Immunotherapy. Part 1 - Proteomics Analysis

Completed
NCT01033344Phase 2

Cat-PAD Exposure Chamber Study

Completed
NCT00867906Phase 2

Safety of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects With Controlled Asthma

Completed
NCT00729508Phase 2

Effectiveness of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects

Completed
NCT00685711Phase 1

Safety of Cat-PAD in Cat Allergic Subjects

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9